A Study of Enasidenib in People With T-Cell Lymphoma
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.
T-cell Lymphoma
DRUG: Enasidenib|DRUG: Rituximab
response rate, a 20% response rate is undesirable and 45% is desirable, 1 year
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.